Immunostaining in Lung Cancer for the Clinician Commonly Used Markers for Differentiating Primary and Metastatic Pulmonary Tumors

被引:12
作者
Carney, John M. [1 ]
Kraynie, Alyssa M. [1 ]
Roggli, Victor L. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pathol, M255 Davison Bldg,200 Trent Dr, Durham, NC 27706 USA
关键词
immunohistochemistry; pulmonary malignancies; differential diagnosis; SQUAMOUS-CELL-CARCINOMA; TRANSCRIPTION FACTOR-I; 2011 INTERNATIONAL ASSOCIATION; MALIGNANT MESOTHELIOMA; IMMUNOHISTOCHEMICAL EVALUATION; PATHOLOGICAL DIAGNOSIS; CONSENSUS STATEMENT; EXPRESSION; UTILITY; BREAST;
D O I
10.1513/AnnalsATS.201501-004FR
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Immunohistochemical stains have become invaluable for the diagnosis of pulmonary malignancies (both primary and metastatic), particularly given the small size of transbronchial and endobronchial biopsies and the increasing need to conserve tissue for molecular studies. There are many panels of immunostains currently available to help differentiate between common types of pulmonary malignancies. It is the purpose of this review to summarize some of the most commonly used immunostains for the distinction of primary pulmonary malignancies from one another in areas with histological overlap and for distinguishing primary pulmonary malignancies from other cancers with which they may be confused. These include differentiating between poorly differentiated adenocarcinoma and poorly differentiated squamous cell carcinoma, small cell/large cell neuroendocrine carcinoma and basaloid carcinoma, and primary and metastatic adenocarcinoma involving the lung. In addition, we address the distinction between mesothelioma and pulmonary adenocarcinoma. Pitfalls in the use of these markers are also addressed. Although not aiming to be comprehensive, this review aims to guide and influence common practice by furthering the clinician's knowledge on using immunohistochemical stains for characterization of pulmonary neoplasms. This summary of frequently used immunohistochemical stains can provide usefulness by allowing accurate characterization of pulmonary tumors, thereby allowing for conservation of tissue for additional molecular testing.
引用
收藏
页码:429 / 435
页数:7
相关论文
共 48 条
[1]  
[Anonymous], AFIP ATLAS TUMOR PAT
[2]  
[Anonymous], ROSAI ACKERMANS SURG
[3]  
[Anonymous], HISTOLOGY PATHOLOGIS
[4]   p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma [J].
Bishop, Justin A. ;
Teruya-Feldstein, Julie ;
Westra, William H. ;
Pelosi, Giuseppe ;
Travis, William D. ;
Rekhtman, Natasha .
MODERN PATHOLOGY, 2012, 25 (03) :405-415
[5]   BASAL-CELL (BASALOID) CARCINOMA OF THE LUNG - A NEW MORPHOLOGICAL AND PHENOTYPIC ENTITY WITH SEPARATE PROGNOSTIC-SIGNIFICANCE [J].
BRAMBILLA, E ;
MORO, D ;
VEALE, D ;
BRICHON, PY ;
STOEBNER, P ;
PARAMELLE, B ;
BRAMBILLA, C .
HUMAN PATHOLOGY, 1992, 23 (09) :993-1003
[6]   The new World Health Organization classification of lung tumours [J].
Brambilla, E ;
Travis, WD ;
Colby, TV ;
Corrin, B ;
Shimosato, Y .
EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (06) :1059-1068
[7]   Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma [J].
Capurro, M ;
Wanless, IR ;
Sherman, M ;
Deboer, G ;
Shi, W ;
Miyoshi, E ;
Filmus, J .
GASTROENTEROLOGY, 2003, 125 (01) :89-97
[8]   The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms [J].
Chang, YL ;
Lee, YC ;
Liao, WY ;
Wu, CT .
LUNG CANCER, 2004, 44 (02) :149-157
[9]  
Chirieac LR, 2011, AM J CANCER RES, V1, P14
[10]   Semiquantitative GATA-3 Immunoreactivity in Breast, Bladder, Gynecologic Tract, and Other Cytokeratin 7-Positive Carcinomas [J].
Clark, Beth Z. ;
Beriwal, Surabhi ;
Dabbs, David J. ;
Bhargava, Rohit .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (01) :64-71